Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness | BMC Cancer | Full Text

Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness | BMC Cancer | Full Text

Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness

Treatment with tumor-Infiltrating Lymphocytes (TIL) is an innovative therapy for advanced melanoma with promising clinical phase I/II study results and likely beneficial cost-effectiveness. As a randomized con...

Authors:Melanie Lindenberg, Valesca Retèl, Maartje Rohaan, Joost van den Berg, John Haanen and Wim van Harten

Citation:BMC Cancer 2020 20:712

Content type:Research article

 

Published on: 31 July 2020

• ViewFull Text
 
• ViewPDF